Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
Charu Aggarwal(UPMC Hillman Cancer Center), Nehal J. Lakhani(Van Andel Institute), Ezio Bonvini(MacroGenics (United States)), Vinod Ganju(Peninsula Health), Paul A. Moore(MacroGenics (United States)), Rosetta Cavallo(MacroGenics (United States)), Dan P. Zandberg(University of Pittsburgh), Yanyan Lou(Jacksonville College), Ralph J. Hauke(Canadian Cancer Society), Jan Baughman(MacroGenics (United States)), Linda Peng(MacroGenics (United States)), Andrew Weickhardt(Peter MacCallum Cancer Centre), Scott Antonia(Moffitt Cancer Center), S. Goldberg(MacroGenics (United States)), Amy Prawira(St Vincent's Hospital Sydney), Sanjeev Kaul(AstraZeneca (United States)), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Mahesh Seetharam(Mayo Clinic in Arizona), Osama E. Rahma(Dana-Farber/Harvard Cancer Center), Anthony M. Joshua(University Health Network), Robert L. Ferris(University of Pittsburgh), Fernanda I. Arnaldez(MacroGenics (United States)), Xiaoyu Zhang(Harbin Medical University), Ariel E. Birnbaum(Rhode Island Hospital), Roger B. Cohen(Memorial Sloan Kettering Cancer Center), Victoria Atkinson(Greenslopes Private Hospital), Alex A. Adjei(Roswell Park Comprehensive Cancer Center), Arash Rezazadeh Kalebasty(Norton Healthcare)
Cited by 140
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k